CRDF vs. ATHA, DTIL, ALGS, ADAP, FRLN, ADPT, KYTX, LXEO, CABA, and ALEC
Should you be buying Cardiff Oncology stock or one of its competitors? The main competitors of Cardiff Oncology include Athira Pharma (ATHA), Precision BioSciences (DTIL), Aligos Therapeutics (ALGS), Adaptimmune Therapeutics (ADAP), Freeline Therapeutics (FRLN), Adaptive Biotechnologies (ADPT), Kyverna Therapeutics (KYTX), Lexeo Therapeutics (LXEO), Cabaletta Bio (CABA), and Alector (ALEC). These companies are all part of the "medical" sector.
Cardiff Oncology (NASDAQ:CRDF) and Athira Pharma (NASDAQ:ATHA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations, community ranking and media sentiment.
Cardiff Oncology received 20 more outperform votes than Athira Pharma when rated by MarketBeat users. Likewise, 62.30% of users gave Cardiff Oncology an outperform vote while only 58.06% of users gave Athira Pharma an outperform vote.
In the previous week, Athira Pharma had 2 more articles in the media than Cardiff Oncology. MarketBeat recorded 4 mentions for Athira Pharma and 2 mentions for Cardiff Oncology. Athira Pharma's average media sentiment score of 1.55 beat Cardiff Oncology's score of 0.62 indicating that Athira Pharma is being referred to more favorably in the news media.
16.3% of Cardiff Oncology shares are held by institutional investors. Comparatively, 57.1% of Athira Pharma shares are held by institutional investors. 7.8% of Cardiff Oncology shares are held by company insiders. Comparatively, 19.8% of Athira Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Cardiff Oncology has a beta of 2.02, meaning that its stock price is 102% more volatile than the S&P 500. Comparatively, Athira Pharma has a beta of 2.83, meaning that its stock price is 183% more volatile than the S&P 500.
Cardiff Oncology currently has a consensus target price of $10.50, suggesting a potential upside of 230.19%. Athira Pharma has a consensus target price of $19.00, suggesting a potential upside of 625.19%. Given Athira Pharma's higher possible upside, analysts clearly believe Athira Pharma is more favorable than Cardiff Oncology.
Athira Pharma has a net margin of 0.00% compared to Cardiff Oncology's net margin of -6,594.92%. Cardiff Oncology's return on equity of -54.54% beat Athira Pharma's return on equity.
Cardiff Oncology has higher revenue and earnings than Athira Pharma. Cardiff Oncology is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.
Summary
Cardiff Oncology and Athira Pharma tied by winning 8 of the 16 factors compared between the two stocks.
Get Cardiff Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRDF and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRDF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardiff Oncology Competitors List
Related Companies and Tools
